Learn More
Sandostatin, a synthetic octapeptide analog of a native hormone somatostatin, was labeled with a commonly available, inexpensive radionuclide, 99mTc, and evaluated for its suitability for in vivo imaging. Labeling was accomplished by reduction of the cystine bridge, which provided two sulfhydryl groups for chelation with 99mTc. The complex was examined for(More)
Vapreotide (RC-160), an octapeptide analog of somatostatin, has a high affinity for somatostatin receptor subtypes SSTR2 and SSTR5. Vapreotide binds differently to the tumors of the breast, ovary, exocrine pancreas, prostate and colon, than octreotide another octapeptide analog of somatostatin. Vapreotide was labeled with Tc-99m, a radionuclide highly(More)
This investigation is based on a hypothesis that a biological response modifier, interferon-alpha-2b (IFN), when conjugated with a specific monoclonal antibody (mAb) and given to tumor-bearing animals before the administration of radiolabeled mAb, may not only augment the tumor uptake but may also impede the liver and blood uptake, because the mAb(More)
Pharmacokinetic and biodistribution studies were conducted in rats on a novel serine protease inhibitor, LEX 032, that was radiolabeled with 131I by the Bolton-Hunter reagent. LEX 032, a genetically engineered recombinant human nonglycosylated serpin, has been shown to have antiinflammatory properties in a number of animal models of inflammation and(More)
Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTC by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111In-DTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a(More)
  • 1